Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The Golden Future In Medicinal Chemistry Perspectives And Resources From Old And New Gold Based Drug Candidates PDF full book. Access full book title The Golden Future In Medicinal Chemistry Perspectives And Resources From Old And New Gold Based Drug Candidates.
| Author | : Alessandro Pratesi |
| Publisher | : Frontiers Media SA |
| Total Pages | : 84 |
| Release | : 2021-05-10 |
| Genre | : Science |
| ISBN | : 2889667510 |
| Author | : Ved Srivastava |
| Publisher | : Royal Society of Chemistry |
| Total Pages | : 589 |
| Release | : 2017-06-22 |
| Genre | : Science |
| ISBN | : 1788011716 |
With potentially high specificity and low toxicity, biologicals offer promising alternatives to small-molecule drugs. Peptide therapeutics have again become the focus of innovative drug development efforts backed up by a resurgence of venture funds and small biotechnology companies. What does it take to develop a peptide-based medicine? What are the key challenges and how are they overcome? What are emerging therapeutics for peptide modalities? This book answers these questions with a holistic story from molecules to medicine, combining the themes of design, synthesis and clinical applications of peptide-based therapeutics and biomarkers. Chapters are written and edited by leaders in the field from industry and academia and they cover the pharmacokinetics of peptide therapeutics, attributes necessary for commercially successful metabolic peptides, medicinal chemistry strategies for the design of peptidase-resistant peptide analogues, disease classes for which peptide therapeutic are most relevant, and regulatory issues and guidelines. The critical themes covered provide essential background information on what it takes to develop peptide-based medicine from a chemistry perspective and views on the future of peptide drugs. This book will be a valuable resource not only as a reference book for the researcher engaged in academic and pharmaceutical setting, from basic research to manufacturing and from organic chemistry to biotechnology, but also a valuable resource to graduate students to understand discovery and development process for peptide-based medicine.
| Author | : Chris G. Kruse |
| Publisher | : IOS Press |
| Total Pages | : 140 |
| Release | : 2008 |
| Genre | : Business & Economics |
| ISBN | : 1586039490 |
"The ninth Solvay Pharmaceutical Conference on Medicinal Chemistry held in Garmisch-Partenkirchen (Germany) September 26-28, 2007"--P. vi.
| Author | : Mukund S. Chorghade |
| Publisher | : John Wiley & Sons |
| Total Pages | : 478 |
| Release | : 2006-07-18 |
| Genre | : Science |
| ISBN | : 047178009X |
From first principles to real-world applications -- here is the first comprehensive guide to drug discovery and development Modern drug discovery and development require the collaborative efforts of specialists in a broadarray of scientific, technical, and business disciplines--from biochemistry to molecular biology, organic chemistry to medicinal chemistry, pharmacology to marketing. Yet surprisingly, until now, there were no authoritative references offering a complete, fully integrated picture of the process. The only comprehensive guide of its kind, this groundbreaking two-volume resource provides an overview of the entire sequence of operations involved in drug discovery and development--from initial conceptualization to commercialization to clinicians and medical practitioners. Volume 1: Drug Discovery describes all the steps in the discovery process, including conceptualizing a drug, creating a library of candidates for testing, screening candidates for in vitro and in vivo activity, conducting and analyzing the results of clinical trials, and modifying a drug as necessary. Volume 2: Drug Development delves into the nitty-gritty details of optimizing the synthetic route, drug manufacturing, outsourcing, and marketing--including drug coloring and delivery methods. Featuring contributions from a world-class team of experts, Drug Discovery and Development: * Features fascinating case studies, including the discovery and development of erythromycin analogs, Tagamet, and Ultiva (remifentanil) * Discusses the discovery of medications for bacterial infections, Parkinson's disease, psoriasis, peptic ulcers, atopic dermatitis, asthma, and cancer * Includes chapters on combinatorial chemistry, molecular biology-based drug discovery, genomics, and chemogenomics Drug Discovery and Development is an indispensable working resource for industrialchemists, biologists, biochemists, and executives who work in the pharmaceutical industry.
| Author | : Tamas Bartfai |
| Publisher | : Academic Press |
| Total Pages | : 377 |
| Release | : 2013-05-18 |
| Genre | : Medical |
| ISBN | : 0124095194 |
The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease. Provides an in-depth, broad perspective on the crisis in drug industry Exposes the disconnect between what society needs and what the drug companies are working on Analyses and projects over 10 years into the future Explains what it means for scientists and society Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat
| Author | : |
| Publisher | : Elsevier |
| Total Pages | : 160 |
| Release | : 2012-05-09 |
| Genre | : Science |
| ISBN | : 0444594426 |
Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems. Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry
| Author | : Bernard Testa |
| Publisher | : Wiley-VCH |
| Total Pages | : 668 |
| Release | : 1993 |
| Genre | : Science |
| ISBN | : |
| Author | : Jie Jack Li |
| Publisher | : CRC Press |
| Total Pages | : 320 |
| Release | : 2021-10-21 |
| Genre | : Medical |
| ISBN | : 1000416011 |
Drug Discovery with Privileged Building Blocks traces back PharmaBlock’s founding philosophy of designing privileged building blocks. High-quality building blocks are crucial not only to biological activities of different molecules but also to ADMET properties, which eventually will impact the success rate of drug discovery projects. A thorough study of how building blocks perform in drug molecules and a regular analysis of new building block structures in the latest researches have proven to be a fruitful strategy to generate novel building blocks. Using this strategy, PharmaBlock has supplied the drug industry with a great number of building blocks, which are increasingly being adopted by drug hunters, and these are identified in this book. Each chapter may be read and studied without learning the previous chapters. This book will be a good starting point for novice medicinal chemists, and veteran medicinal chemists will find it useful as well. Key Feature The book covers privileged building blocks appearing most frequently on patents for novel drugs. The latest relevant tactics are explained in the context of drug design and medicinal chemistry. Key synthesis, especially large-scale synthesis, is described. The most recent literature references are cited.
| Author | : Chris G. Kruse |
| Publisher | : |
| Total Pages | : 129 |
| Release | : 2008 |
| Genre | : Medical |
| ISBN | : 9781607503910 |
The scope of this book is that the pharmaceutical industry must change the way it operates. The editors of this book feel that the current business model is economically unsustainable and incapable to meet expectations of modern society. The number of novel medications in the global industry pipeline is insufficient to suffice demand of the markets, the financial performance of several companies is declining, sales and marketing costs are rising, regulatory constraints are increasingly challenging and overall reputation of industry is tarnishing. Unmet medical needs must be better addressed and tangible benefits need to be exposed in order to be rewarded by healthcare payers. In addition, the focus is shifting from simple treatment of the ill to preventative measures and health management. This volume addresses newest development in synthetic and medicinal chemistry with the emphasis on global challenges.
| Author | : Arnab De |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 89 |
| Release | : 2012-08-18 |
| Genre | : Medical |
| ISBN | : 1461448751 |
Macromolecular (specifically peptide-based) drugs could potentially be highly effective medicines. However they have a relatively short duration of action and variable therapeutic index. An example of such a peptide is Glucagon-like Peptide I which could potentially be used as a revolutionary drug for diabetes. This is because it stimulates insulin only when the blood glucose level is high thereby reducing the risk of hypoglycemia (a significant disadvantage of using insulin is that an insulin overdose is the single most potent cause of life-threatening hypoglycemia). However it’s short duration of action (half-life of 2 minutes in plasma) precludes its therapeutic use. In this volume, the use of novel therapeutics like GLP1 as an alternative to tradition insulin-based drugs in diabetes is described. Application of Peptide-Based Prodrug Chemistry in Drug Development elucidates the traditional concept of prodrugs as “specialized non-toxic protective groups used in a transient manner to alter or to eliminate certain limiting properties in the parent small molecule” (IUPAC definition). It goes on to provide insight into how prodrugs of peptides (with GLP1 as an example) could be appropriately used to extend the biological half life, broaden the therapeutic index of macromolecules and improve the pharmacodynamics of such drugs. Author explains the logic behind designing peptide prodrugs, synthetic procedures and bioassays to examine the conversion of the prodrug to the drug under therapeutic conditions. The prodrugs described slowly convert to the parent drug at physiological conditions of 37C and pH 7.2 driven by their inherent chemical instability without the need of any enzymatic cleavage. The diketopiperazine and diketomorpholine (DKP and DMP) strategies for prodrug conversion are demonstrated in detail with special emphasis on the chemical flexibility that it offers to develop prodrugs with variable time actions. This book will be of useful to chemists, biochemists, medicinal chemists, biologists and people in the medical profession (doctors). It may be used in undergraduate classes but will certainly help post-graduate students and advanced professionals. The author is grateful to Prof. Richard DiMarchi (Standiford H. Cox Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University) for valuable suggestions. The foreword for the book has been written by Prof. Jean Martinez, (Legion d'Honneur awarded by the French Republic; Professor of Chemistry and Medicinal Chemistry of the University of Montpellier, France; and Chairman of European Peptide Society, 2002-2010).
